These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 25835443)

  • 1. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
    Bakris GL; Townsend RR; Flack JM; Brar S; Cohen SA; D'Agostino R; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
    J Am Coll Cardiol; 2015 Apr; 65(13):1314-1321. PubMed ID: 25835443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Bhatt DL; Vaduganathan M; Kandzari DE; Leon MB; Rocha-Singh K; Townsend RR; Katzen BT; Oparil S; Brar S; DeBruin V; Fahy M; Bakris GL;
    Lancet; 2022 Oct; 400(10361):1405-1416. PubMed ID: 36130612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
    Bakris GL; Townsend RR; Liu M; Cohen SA; D'Agostino R; Flack JM; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
    J Am Coll Cardiol; 2014 Sep; 64(11):1071-8. PubMed ID: 24858423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
    Kario K; Bhatt DL; Brar S; Cohen SA; Fahy M; Bakris GL
    Hypertension; 2015 Dec; 66(6):1130-7. PubMed ID: 26558819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
    Townsend RR; Mahfoud F; Kandzari DE; Kario K; Pocock S; Weber MA; Ewen S; Tsioufis K; Tousoulis D; Sharp ASP; Watkinson AF; Schmieder RE; Schmid A; Choi JW; East C; Walton A; Hopper I; Cohen DL; Wilensky R; Lee DP; Ma A; Devireddy CM; Lea JP; Lurz PC; Fengler K; Davies J; Chapman N; Cohen SA; DeBruin V; Fahy M; Jones DE; Rothman M; Böhm M;
    Lancet; 2017 Nov; 390(10108):2160-2170. PubMed ID: 28859944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.
    Kandzari DE; Böhm M; Mahfoud F; Townsend RR; Weber MA; Pocock S; Tsioufis K; Tousoulis D; Choi JW; East C; Brar S; Cohen SA; Fahy M; Pilcher G; Kario K;
    Lancet; 2018 Jun; 391(10137):2346-2355. PubMed ID: 29803589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal denervation in moderate treatment-resistant hypertension.
    Ott C; Mahfoud F; Schmid A; Ditting T; Sobotka PA; Veelken R; Spies A; Ukena C; Laufs U; Uder M; Böhm M; Schmieder RE
    J Am Coll Cardiol; 2013 Nov; 62(20):1880-6. PubMed ID: 23850901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.
    Böhm M; Mahfoud F; Ukena C; Hoppe UC; Narkiewicz K; Negoita M; Ruilope L; Schlaich MP; Schmieder RE; Whitbourn R; Williams B; Zeymer U; Zirlik A; Mancia G;
    Hypertension; 2015 Apr; 65(4):766-74. PubMed ID: 25691618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
    ; Esler MD; Krum H; Sobotka PA; Schlaich MP; Schmieder RE; Böhm M
    Lancet; 2010 Dec; 376(9756):1903-9. PubMed ID: 21093036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial.
    Esler MD; Krum H; Schlaich M; Schmieder RE; Böhm M; Sobotka PA;
    Circulation; 2012 Dec; 126(25):2976-82. PubMed ID: 23248063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs.
    Mauri L; Kario K; Basile J; Daemen J; Davies J; Kirtane AJ; Mahfoud F; Schmieder RE; Weber M; Nanto S; Azizi M
    Am Heart J; 2018 Jan; 195():115-129. PubMed ID: 29224639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SYMPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients - .
    Kario K; Ogawa H; Okumura K; Okura T; Saito S; Ueno T; Haskin R; Negoita M; Shimada K;
    Circ J; 2015; 79(6):1222-9. PubMed ID: 25912693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal denervation in patients with resistant hypertension: six-month results.
    Dores H; de Sousa Almeida M; de Araújo Gonçalves P; Branco P; Gaspar A; Sousa H; Canha Gomes A; Andrade MJ; Carvalho MS; Campante Teles R; Raposo L; Mesquita Gabriel H; Pereira Machado F; Mendes M
    Rev Port Cardiol; 2014 Apr; 33(4):197-204. PubMed ID: 24472425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled trial of renal denervation for resistant hypertension.
    Bhatt DL; Kandzari DE; O'Neill WW; D'Agostino R; Flack JM; Katzen BT; Leon MB; Liu M; Mauri L; Negoita M; Cohen SA; Oparil S; Rocha-Singh K; Townsend RR; Bakris GL;
    N Engl J Med; 2014 Apr; 370(15):1393-401. PubMed ID: 24678939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension.
    Desch S; Okon T; Heinemann D; Kulle K; Röhnert K; Sonnabend M; Petzold M; Müller U; Schuler G; Eitel I; Thiele H; Lurz P
    Hypertension; 2015 Jun; 65(6):1202-8. PubMed ID: 25824248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of hypertension control and clinical course of patients excluded from the SYMPLICITY HTN-3 trial.
    Yerasi C; Baker NC; Jonnalagadda AK; Torguson R; Singh S; Vies J; Waksman R
    J Am Soc Hypertens; 2015 Dec; 9(12):959-65. PubMed ID: 26687550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Mahfoud F; Kandzari DE; Kario K; Townsend RR; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Dimitriadis K; Choi JW; East C; D'Souza R; Sharp ASP; Ewen S; Walton A; Hopper I; Brar S; McKenna P; Fahy M; Böhm M
    Lancet; 2022 Apr; 399(10333):1401-1410. PubMed ID: 35390320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.
    Mahfoud F; Ukena C; Schmieder RE; Cremers B; Rump LC; Vonend O; Weil J; Schmidt M; Hoppe UC; Zeller T; Bauer A; Ott C; Blessing E; Sobotka PA; Krum H; Schlaich M; Esler M; Böhm M
    Circulation; 2013 Jul; 128(2):132-40. PubMed ID: 23780578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension.
    Weber MA; Kirtane AJ; Weir MR; Radhakrishnan J; Das T; Berk M; Mendelsohn F; Bouchard A; Larrain G; Haase M; Diaz-Cartelle J; Leon MB
    JACC Cardiovasc Interv; 2020 Feb; 13(4):461-470. PubMed ID: 32081240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.
    Azizi M; Sharp ASP; Fisher NDL; Weber MA; Lobo MD; Daemen J; Lurz P; Mahfoud F; Schmieder RE; Basile J; Bloch MJ; Saxena M; Wang Y; Sanghvi K; Jenkins JS; Devireddy C; Rader F; Gosse P; Claude L; Augustin DA; McClure CK; Kirtane AJ;
    Circulation; 2024 Mar; 149(10):747-759. PubMed ID: 37883784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.